These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine. Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568 [TBL] [Abstract][Full Text] [Related]
3. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells. Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922 [TBL] [Abstract][Full Text] [Related]
4. HLA-E Fang YH; Wang SPH; Liao IC; Tsai KJ; Huang PH; Yang PJ; Yen CJ; Liu PY; Shan YS; Liu YW Adv Healthc Mater; 2023 Nov; 12(29):e2301186. PubMed ID: 37672681 [TBL] [Abstract][Full Text] [Related]
5. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519 [TBL] [Abstract][Full Text] [Related]
6. Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity. Chen Y; Zhou Y; Zhou Z; Fang Y; Ma L; Zhang X; Xiong J; Liu L Stem Cell Res Ther; 2023 Jan; 14(1):11. PubMed ID: 36691086 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells. Ogawa T; Kan-O K; Shiota A; Fujita A; Ishii Y; Fukuyama S; Matsumoto K Front Immunol; 2021; 12():767666. PubMed ID: 34899719 [TBL] [Abstract][Full Text] [Related]
8. KSCBi005-A-8(hiPSC-PD-L1KO), a PD-L1 knockout human induced pluripotent stem cell line for demonstrating the role of the PD-1/PD-L1 axis. Han HJ; Kim JH Stem Cell Res; 2023 Oct; 72():103196. PubMed ID: 37690432 [TBL] [Abstract][Full Text] [Related]
9. Transient characteristics of universal cells on human-induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources. Sung TC; Jiang YP; Hsu JY; Ling QD; Chen H; Kumar SS; Chang Y; Hsu ST; Ye Q; Higuchi A Cell Prolif; 2021 Mar; 54(3):e12995. PubMed ID: 33522648 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491 [TBL] [Abstract][Full Text] [Related]
12. Universal and hypoimmunogenic pluripotent stem cells for clinical usage. Sung TC; Maitiruze K; Pan J; Gong J; Bai Y; Pan X; Higuchi A Prog Mol Biol Transl Sci; 2023; 199():271-296. PubMed ID: 37678974 [TBL] [Abstract][Full Text] [Related]
13. [Progress in PD-1/PD-L1, PD-L2 signaling pathway and its role in host anti-tuberculosis immunity]. Yu XW; Zhang JA; Xie JP Zhonghua Jie He He Hu Xi Za Zhi; 2024 May; 47(5):485-489. PubMed ID: 38706074 [TBL] [Abstract][Full Text] [Related]
14. Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial. Miwa S; Nojima T; Alomesen AA; Ikeda H; Yamamoto N; Nishida H; Hayashi K; Takeuchi A; Igarashi K; Higuchi T; Yonezawa H; Araki Y; Morinaga S; Asano Y; Tsuchiya H Clin Transl Oncol; 2021 Aug; 23(8):1620-1629. PubMed ID: 33635466 [TBL] [Abstract][Full Text] [Related]
15. Human stem cell derived beta-like cells engineered to present PD-L1 improve transplant survival in NOD mice carrying human HLA class I. Santini-González J; Castro-Gutierrez R; Becker MW; Rancourt C; Russ HA; Phelps EA Front Endocrinol (Lausanne); 2022; 13():989815. PubMed ID: 36506044 [TBL] [Abstract][Full Text] [Related]
16. Generation of universal and hypoimmunogenic human pluripotent stem cells. Ye Q; Sung TC; Yang JM; Ling QD; He Y; Higuchi A Cell Prolif; 2020 Dec; 53(12):e12946. PubMed ID: 33174655 [TBL] [Abstract][Full Text] [Related]
17. Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and their derivatives. Chen HF; Yu CY; Chen MJ; Chou SH; Chiang MS; Chou WH; Ko BS; Huang HP; Kuo HC; Ho HN Cell Transplant; 2015; 24(5):845-64. PubMed ID: 24144439 [TBL] [Abstract][Full Text] [Related]
18. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Deuse T; Hu X; Gravina A; Wang D; Tediashvili G; De C; Thayer WO; Wahl A; Garcia JV; Reichenspurner H; Davis MM; Lanier LL; Schrepfer S Nat Biotechnol; 2019 Mar; 37(3):252-258. PubMed ID: 30778232 [TBL] [Abstract][Full Text] [Related]
19. Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics. Cysneiros MAPC; Cirqueira MB; Barbosa LF; Chaves de Oliveira Ê; Morais LK; Wastowski IJ; Floriano VG PLoS One; 2024; 19(7):e0305648. PubMed ID: 38954689 [TBL] [Abstract][Full Text] [Related]
20. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. Pittet CL; Newcombe J; Prat A; Arbour N J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]